COVID-19 and Anticoagulants

19 December 2022

Recent evidence shows potentially significant drug interactions may occur between COVID-19 treatments, including Paxlovid, Lagevrio and Veklury and anticoagulants. Broadly speaking:

Lagevrio – there are no reported significant drug interactions with anticoagulants, particularly with Direct Oral Anticoagulants (DOACs) at this time.

Paxlovid – there are important interactions with anticoagulants, particularly with DOACs and also with warfarin.

Veklury – may increase or decrease the anticoagulant effect of warfarin.  Such interactions can impact on laboratory monitoring of anticoagulant use and the safe use of anticoagulants. 

It is advised that drug interactions are checked if patients are commenced on the above-listed COVID-19 treatments. Refer to the product information sheets; additionally, the following links provide information on potentially significant drug interactions: 

It is recommended that you consult with a pharmacist as well as the appropriate clinical services if potentially significant drug interactions are identified.

General News

31
Jan

BiomeBank

Adelaide’s BiomeBank recently made the news when they became...

27
Jan

Regional Scholarship Now Open

Sarah Wall is a 2022 recipient of the SA Pathology Regional ...

17
Jan

How to feel your best after a blood test

Although our staff are trained to minimise any problems asso...

3
Jan

The banks that give back

Each year - especially across the festive season, Australian...

20
Dec

Ivan’s life-saving legacy

In early 2023 SA Pathology will bid farewell to Dr Ivan Bast...